Hemoptysis¶
Chapter 41 | Hemoptysis
KEY CLINICAL POINTS¶
- Hemoptysis is the expectoration of blood from the lower respiratory tract, with volume and frequency critical for assessing severity.
- Common causes include infections (e.g., tuberculosis, bronchiectasis), malignancy, and vascular disease.
- Massive hemoptysis (>150 mL/24h or >100 mL/h) requires emergent intervention; nonmassive hemoptysis is more common.
- Diagnostic evaluation includes chest imaging, bronchoscopy, and laboratory tests to differentiate etiologies.
- Management depends on underlying cause, with bronchoscopy often used for hemostasis and source identification.
1. DEFINITION & OVERVIEW¶
Hemoptysis is the expectoration of blood originating from the lower respiratory tract. It must be differentiated from hematemesis (GI bleeding) or epistaxis. The amount of blood (volume and frequency) is critical for assessing severity and guiding management.
Classification of Hemoptysis by Volume¶
| Volume | Definition | Management |
|---|---|---|
| <150 mL/24h | Nonmassive hemoptysis | Observation, bronchoscopy, and source identification |
| >150 mL/24h or >100 mL/h | Massive hemoptysis | Emergent intervention (bronchoscopy, embolization, surgery) |
1.1 Global Considerations¶
Air pollution, occupational exposures, and ambient chemicals contribute to chronic cough and hemoptysis. In tuberculosis-endemic regions, active TB must be considered. Vaping-induced lung injury is a recently identified cause of hemoptysis and diffuse alveolar hemorrhage (DAH).
1.2 Anatomy & Physiology¶
Blood supply to the lungs is dual: pulmonary circulation (low-pressure, gas exchange) and bronchial circulation (high-pressure, from aorta). Most hemoptysis originates from bronchial circulation, which can make bleeding difficult to control.
2. EPIDEMIOLOGY¶
In the US, viral bronchitis, bronchiectasis, and malignancy are most common causes. In tuberculosis-endemic regions, TB is the leading cause. Chronic cough with normal imaging may indicate benign causes, while persistent hemoptysis requires further investigation.
2.1 Risk Factors¶
Smoking, chronic lung disease (e.g., cystic fibrosis), immunocompromise, anticoagulation, and occupational exposures increase risk. Recent immigrants from endemic areas may present with Paragonimiasis.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
Common causes include infections (TB, fungal, bacterial), malignancy, vascular abnormalities, and mechanical injury. Pathogenesis involves inflammation, vascular damage, or neovascularization in bronchiectasis. DAH is caused by immune-mediated capillaritis (e.g., lupus, Goodpasture syndrome).
Common Causes of Hemoptysis¶
| Cause | Prevalence | Key Features |
|---|---|---|
| Infections (TB, bronchiectasis) | Common in US and endemic regions | Cough, sputum, cavitary lesions |
| Malignancy | Common in smokers | Weight loss, hemoptysis with mass effect |
| Vascular Causes | Rare | Sudden onset, massive bleeding |
| Coagulopathy | Varies | Minor trauma causes bleeding |
3.1 Infections¶
Viral bronchitis is most common. Bacterial causes include Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Fungal infections (e.g., Aspergillus, Nocardia) can cause cavitary lung disease with hemoptysis.
3.2 Malignancy¶
Bronchogenic carcinoma (small-cell, squamous cell) and metastases (e.g., melanoma, Kaposi’s sarcoma) can cause hemoptysis via airway invasion or vascular erosion.
3.3 Vascular Causes¶
Arteriovenous malformations, pulmonary embolism, and aortobronchial fistulas are rare but significant causes. Rupture of a pulmonary artery aneurysm (Rasmussen’s aneurysm) can lead to massive bleeding.
4. CLINICAL FEATURES¶
Symptoms include cough with blood, chest pain, dyspnea, and hemoptysis volume. Signs may include clubbing, hemodynamic instability, or signs of bleeding diathesis. Massive hemoptysis may present with blood filling airways, leading to asphyxiation.
4.1 Differential Diagnosis¶
Differentiate from hematemesis (GI bleeding), epistaxis, and pseudohemoptysis (e.g., upper airway bleeding). Consider DAH in patients with pulmonary-renal syndromes (e.g., granulomatosis with polyangiitis).
5. DIFFERENTIAL DIAGNOSIS¶
Key differentials include tuberculosis, bronchiectasis, lung cancer, fungal infections, pulmonary embolism, and coagulopathy. Vaping-induced lung injury and Paragonimiasis are emerging causes in specific populations.
5.1 Infections¶
TB, fungal infections (Aspergillus, Nocardia), and bacterial pneumonia (e.g., Klebsiella) must be considered, especially in immunocompromised patients.
5.2 Malignancy¶
Carcinoid tumors, bronchogenic carcinoma, and metastases may present with hemoptysis as a first symptom.
6. INVESTIGATIONS & DIAGNOSIS¶
Initial workup includes chest X-ray, CBC, coagulation studies, and CT scan. Bronchoscopy is essential for source identification and hemostasis. Pulmonary function tests and sputum analysis may guide infection or malignancy workup.
Diagnostic Criteria for Massive Hemoptysis¶
| Criteria | Definition |
|---|---|
| Volume | >150 mL/24h or >100 mL/h |
| Clinical Features | Hemodynamic instability, airway obstruction |
| Management | Emergent bronchoscopy, embolization, or surgery |
6.1 Diagnostic Algorithm¶
- Assess hemoptysis volume and severity. 2. Obtain chest X-ray and CT scan. 3. Perform bronchoscopy for visualization and intervention. 4. Test for TB, fungal, or bacterial pathogens. 5. Evaluate coagulation and platelet function.
7. MANAGEMENT & TREATMENT¶
Nonmassive hemoptysis is managed with bronchoscopy, anticoagulation reversal, and source-specific treatment. Massive hemoptysis requires bronchial artery embolization, surgical resection, or bronchial artery ligation. Supportive care includes oxygen, hemodynamic stabilization, and airway protection.
Management of Hemoptysis by Severity¶
| Severity | Initial Steps | Interventions |
|---|---|---|
| Nonmassive | Bronchoscopy, source identification | Anticoagulation management, bronchodilators |
| Massive | Airway protection, hemodynamic support | Bronchial artery embolization, surgery |
7.1 Pharmacologic Therapy¶
Anticoagulation reversal (e.g., vitamin K, prothrombin complex concentrate) and bronchodilators may be used. Corticosteroids are considered for DAH or inflammatory causes.
7.2 Interventional Approaches¶
Bronchoscopy with clot removal or embolization is first-line. Surgical resection may be required for tumors or vascular malformations.
8. PROGNOSIS & COMPLICATIONS¶
Prognosis depends on underlying cause. Massive hemoptysis has high mortality (5–15% of cases) due to airway obstruction or exsanguination. Complications include respiratory failure, infection, and bleeding from coagulopathy.
8.1 Complications¶
Airway obstruction, hypovolemic shock, pulmonary infarction, and secondary infections are common. Chronic hemoptysis may lead to anemia or respiratory failure.
9. SPECIAL CONSIDERATIONS¶
In pregnancy, hemoptysis may be due to TB, bronchiectasis, or coagulopathy. In pediatrics, infections (e.g., TB, fungal) are more common. Elderly patients may have underlying malignancy or coagulopathy. Vaping-induced lung injury is a growing concern in young adults.
9.1 Coagulopathy¶
Patients on anticoagulants or with bleeding disorders are at risk for minor trauma-induced hemoptysis. Reversal agents and platelet transfusion may be required.
10. KEY POINTS & CLINICAL PEARLS¶
- Hemoptysis volume and pattern are critical for triage.
- Bronchoscopy is essential for diagnosis and hemostasis.
- Massive hemoptysis requires emergent intervention.
- Consider TB, bronchiectasis, and malignancy in differential.
- Vaping-induced lung injury and Paragonimiasis are emerging causes.